---
audienceLevel: patient
cancerTypes:
- eye
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- cancer-type
title: Intraocular (Eye) Melanoma Research - NCI
url: https://www.cancer.gov/types/eye/research
version: v1
---

# Intraocular (Eye) Melanoma Research - NCI

# Intraocular (Eye) Melanoma Research

- [Immunotherapy Drug Tebentafusp Improves Survival in Advanced Uveal Melanoma](/news-events/cancer-currents-blog/2021/tebentafusp-uveal-melanoma-improves-survival)

Posted: April 29, 2021

In a large trial, tebentafusp helped patients with uveal melanoma live longer than patients who received other treatments for the disease. Uveal melanoma is an aggressive cancer of the eye, and many patients do not survive for a year once it has spread.
